Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.

MLA

Dipetrillo, Thomas, et al. “Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer: A Phase 2 Trial.” American Journal of Clinical Oncology, vol. 35, no. 1, Feb. 2012, pp. 64–67. EBSCOhost, https://doi.org/10.1097/COC.0b013e318201a126.

APA

Dipetrillo, T., Suntharalingam, M., Ng, T., Fontaine, J., Horiba, N., Oldenburg, N., Perez, K., Birnbaum, A., Battafarano, R., Burrows, W., & Safran, H. (2012). Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. American Journal of Clinical Oncology, 35(1), 64–67. https://doi.org/10.1097/COC.0b013e318201a126

Chicago

Dipetrillo, Thomas, Mohan Suntharalingam, Thomas Ng, Jacques Fontaine, Naomi Horiba, Nicklas Oldenburg, Kimberly Perez, et al. 2012. “Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer: A Phase 2 Trial.” American Journal of Clinical Oncology 35 (1): 64–67. doi:10.1097/COC.0b013e318201a126.